Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empesertib + Paclitaxel in Advanced Malignancies
NCT02138812Phase 1Terminated
- Sponsor
- Bayer
- Start
- May 2014
- Primary completion
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of empesertib in solid tumor (advanced stage) and triple-negative breast cancer (TNBC), sponsored by Bayer. Primary endpoints: Maximum Tolerated Dose up to 2 years, Adverse Events up to 2 years and 2 more. Started May 2014; status: terminated.
02
Drugs
empesertib
03
Conditions
solid tumor (advanced stage)triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02138812.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02138812.